Abstract:90% of therapeutic programs that enter clinical trials ultimately fail. Human genetic variation provides a set of "natural experiments" that can inform successful strategies for therapeutic discovery. Previous work has estimated that drug targets with human genetics supported mechanisms have a 2-3x increased likelihood of succeeding in the clinic compared to those without. 23andMe, Inc. is a direct-to-consumer genetics company that has created a human genetics dataset approximately an order of magnitude larger in sample size than current publically available cohorts. As of 2024, 23andMe has approximately 15 million individuals with genotype and phenotype data, of which ~80% consent to participation in research. In this work, we explore how both the scale of the genetic data and improved methods to link genetic associations to putative causal genes impact the prediction of clinical success. Comparing the total number of target-indication pairs that have reached at least phase I that are also supported by genetic evidence, the number of target-indication pairs with support from 23andMe is 60% greater than that with support from all GWAS datasets in the public domain. Including 23andMe genetic evidence approximately doubles the number of target-indication pairs in the clinic that are supported by human genetics. Furthermore, we show that genetic associations derived from entirely self-reported phenotypes are 2-3x enriched for clinical success, just as for clinically derived phenotypes. In contrast to conclusions from the recent publication of Minikel et al., we found that minor allele frequencies and effect sizes from GWAS influence the relative success estimates for program approvals, and that drug programs supported by rare and large effect associations have greater (3-4x) likelihood to be approved compared to common variant associations with small effects. Finally, improved gene mapping to identify the likely causal genes underlying genetic associations can result in up to 4-5x enrichment for trial success. With the increased power and scale of the 23andMe genetic dataset, we identify an expansive set of opportunities that may be pursued in the clinic, emphasizing the importance of cohort size and gene mapping confidence in deriving clinical value.

Validating therapeutic targets through human genetics

From target discovery to clinical drug development with human genetics

Target Discovery and Validation in the Post-Genomic Era

Using human genetics to improve safety assessment of therapeutics

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval

Prioritising genetic findings for drug target identification and validation

Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine

Genetic variation in human drug-related genes

Selection and Validation of Drug Targets

Can Medical Genetics and Evolutionary Biology Inspire Drug Target Identification?

Disease coverage of human genome-wide association studies and pharmaceutical research and development

Challenges in constructing genetic instruments for pharmacologic therapies

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics

Chemical Genetic Validation of GWAS-derived Disease Loci

An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci

In silico prediction of novel therapeutic targets using gene–disease association data

The impact on clinical success from the 23andMe cohort

Unexplored Therapeutic Opportunities in the Human Genome

Genetic drug target validation using Mendelian randomisation

Utilizing ClinGen gene‐disease validity and dosage sensitivity curations to inform variant classification

Genetic factors associated with reasons for clinical trial stoppage